Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-27 · 1381 Präparate · 72104 Quellenpassagen · 204 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Targretin
Targretin 75 mg soft capsules · Abschnitt 4.5 · PDF-Seite 5
HOS-091527 · Präparat HOS-084349
Caution is advised in case of combination with CYP3A4 substrates having a narrow therapeutic
margin i.e. immunosuppressive agents (cyclosporine, tacrolimus, sirolimus) as well as
CYP3A4-metabolised cytotoxics, i.e. cyclophosphamide, etoposide, finasteride, ifosfamide,
tamoxifen, vinca-alcaloids.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): finasteride (HOS-091528) tamoxifen (HOS-088380) etoposide (HOS-086021) ifosfamide (HOS-091529) tacrolimus (HOS-085202) cyclophosphamide (HOS-084539) sirolimus (HOS-085172) cyclosporine (HOS-084512)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-08-12T12:14:00Z · SHA-256 3bf4d2f2fd7cbd6812f185953fbdb6223f58862715009080d9c1b2058c9f08b5 · Passage 998c3b3a660fadbd0afbd519254258d77ac0a27f6b9f61c16422b0e3d345032e · Zeichen 608–904 im Abschnitt
Wechselwirkungen · Emend
EMEND 125 mg hard capsules EMEND 80 mg hard capsules · Abschnitt 4.5 · PDF-Seite 5
HOS-112516 · Präparat HOS-093697
Chemotherapeutic medicinal products
In pharmacokinetic studies, EMEND, when given as a regimen of 125 mg on Day 1 and 80 mg/day on
Days 2 and 3, did not influence the pharmacokinetics of docetaxel administered intravenously on
Day 1 or vinorelbine administered intravenously on Day 1 or Day 8. Because the effect of EMEND on
the pharmacokinetics of orally administered CYP3A4 substrates is greater than the effect of EMEND
on the pharmacokinetics of intravenously administered CYP3A4 substrates, an interaction with orally
administered chemotherapeutic medicinal products metabolised primarily or partly by CYP3A4 (e.g.,
etoposide, vinorelbine) cannot be excluded. Caution is advised and additional monitoring may be
appropriate in patients receiving medicinal products metabolised primarily or partly by CYP3A4 (see
section 4.4). Postmarketing events of neurotoxicity, a potential adverse reaction of ifosfamide, have
been reported after aprepitant and ifosfamide co-administration.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): etoposide (HOS-086021) ifosfamide (HOS-091529) docetaxel (HOS-084505) vinorelbine (HOS-112517)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-10-24T11:24:00Z · SHA-256 afd6062a51e59b36e448c9117685894e4529fcde2f5e673f4401f91bb32d7081 · Passage 89645b6df870cf474bf37feb3044c4bc8659d138a2e7182c037f0defac062724 · Zeichen 3111–4094 im Abschnitt
Wechselwirkungen · Emend
EMEND 125 mg powder for oral suspension · Abschnitt 4.5 · PDF-Seite 22–23
HOS-112577 · Präparat HOS-093697
22
Day 1 or vinorelbine administered intravenously on Day 1 or Day 8. Because the effect of EMEND on
the pharmacokinetics of orally administered CYP3A4 substrates is greater than the effect of EMEND
on the pharmacokinetics of intravenously administered CYP3A4 substrates, an interaction with orally
administered chemotherapeutic medicinal products metabolised primarily or partly by CYP3A4 (e.g.,
etoposide, vinorelbine) cannot be excluded. Caution is advised and additional monitoring may be
appropriate in patients receiving medicinal products metabolised primarily or partly by CYP3A4 (see
section 4.4). Postmarketing events of neurotoxicity, a potential adverse reaction of ifosfamide, have
been reported after aprepitant and ifosfamide co-administration.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): etoposide (HOS-086021) ifosfamide (HOS-091529) vinorelbine (HOS-112517)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-10-24T11:24:00Z · SHA-256 afd6062a51e59b36e448c9117685894e4529fcde2f5e673f4401f91bb32d7081 · Passage b237ddaa2c1c30ed88c48f806a99352ff4837e83b928a8742dad3cec164759ca · Zeichen 3334–4094 im Abschnitt
Wechselwirkungen · Ivemend
IVEMEND 150 mg powder for solution for infusion. · Abschnitt 4.5 · PDF-Seite 7
HOS-117438 · Präparat HOS-094609
Chemotherapeutic medicinal products
Interaction studies with fosaprepitant 150 mg and chemotherapeutic medicinal products have not been
conducted; however, based on studies with oral aprepitant and docetaxel and vinorelbine, IVEMEND
150 mg is not expected to have a clinically relevant interaction with intravenously administered
docetaxel and vinorelbine. An interaction with orally administered chemotherapeutic medicinal
products metabolised primarily or partly by CYP3A4 (e.g., etoposide, vinorelbine) cannot be
excluded. Caution is advised and additional monitoring may be appropriate in patients receiving
medicinal products metabolised primarily or partly by CYP3A4 (see section 4.4). Postmarketing
events of neurotoxicity, a potential adverse reaction of ifosfamide, have been reported after aprepitant
and ifosfamide co-administration.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): aprepitant (HOS-112506) etoposide (HOS-086021) ifosfamide (HOS-091529) docetaxel (HOS-084505) vinorelbine (HOS-112517)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-05T14:57:00Z · SHA-256 9e19bc1fa93d788029c9702424aacb9622fe408d4db1dbe0bc9e0ad1d449f179 · Passage b78fc24de0358af2b4584638fa3e208590245fef03e4d180698051baf33c81fe · Zeichen 2891–3735 im Abschnitt
Wechselwirkungen · Tepadina
TEPADINA 15 mg powder for concentrate for solution for infusion TEPADINA 100 mg powder for concentrate for solution for infusion · Abschnitt 4.5 · PDF-Seite 7
HOS-210371 · Präparat HOS-154509
Thiotepa is a weak inhibitor for CYP2B6, and may thereby potentially increase plasma concentrations
of substances metabolised via CYP2B6, such as ifosfamide, tamoxifen, bupropion, efavirenz and
cyclophosphamide. CYP2B6 catalyzes the metabolic conversion of cyclophosphamide to its active
form 4-hydroxycyclophosphamide (4-OHCP) and co-administration of thiotepa may therefore lead to
decreased concentrations of the active 4-OHCP. Therefore, a clinical monitoring should be exercised
during the concomitant use of thiotepa and these medicinal products.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): bupropion (HOS-086329) tamoxifen (HOS-088380) ifosfamide (HOS-091529) lead (HOS-085592) cyclophosphamide (HOS-084539) efavirenz (HOS-087947) 4-hydroxycyclophosphamide (HOS-210375)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-02-24T14:00:00Z · SHA-256 42c8bab87a55159cb982d55f577a064273549ce149f75b75dbf4d5650be413bc · Passage 02fee406a06fed33cf20b2e58b8f5c3da3663e1afa93c280704add454e4e3420 · Zeichen 992–1544 im Abschnitt
Wechselwirkungen · Tepadina
TEPADINA 200 mg powder and solvent for solution for infusion TEPADINA 400 mg powder and solvent for solution for infusion · Abschnitt 4.5 · PDF-Seite 24
HOS-210415 · Präparat HOS-154509
Thiotepa is a weak inhibitor for CYP2B6, and may thereby potentially increase plasma concentrations
of substances metabolised via CYP2B6, such as ifosfamide, tamoxifen, bupropion, efavirenz and
cyclophosphamide. CYP2B6 catalyzes the metabolic conversion of cyclophosphamide to its active
form 4-hydroxycyclophosphamide (4-OHCP) and co-administration of thiotepa may therefore lead to
decreased concentrations of the active 4-OHCP. Therefore, a clinical monitoring should be exercised
during the concomitant use of thiotepa and these medicinal products.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): bupropion (HOS-086329) tamoxifen (HOS-088380) ifosfamide (HOS-091529) lead (HOS-085592) cyclophosphamide (HOS-084539) efavirenz (HOS-087947) 4-hydroxycyclophosphamide (HOS-210375)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-02-24T14:00:00Z · SHA-256 42c8bab87a55159cb982d55f577a064273549ce149f75b75dbf4d5650be413bc · Passage 02fee406a06fed33cf20b2e58b8f5c3da3663e1afa93c280704add454e4e3420 · Zeichen 992–1544 im Abschnitt
Wechselwirkungen · Mysimba
Mysimba 8 mg/90 mg prolonged-release tablets · Abschnitt 4.5 · PDF-Seite 9
HOS-130330 · Präparat HOS-096899
Co-administration of medicinal products that may inhibit the metabolism of bupropion via CYP2B6
isoenzyme (e.g., CYP2B6 substrates: cyclophosphamide, ifosfamide, and CYP2B6 inhibitors:
orphenadrine, ticlopidine, clopidogrel), may result in increased bupropion plasma levels and lower
levels of active metabolite hydroxybupropion. The clinical consequences of the inhibition of the
metabolism of bupropion via CYP2B6 enzyme and the consequent changes in the
bupropion-hydroxybupropion ratio are currently unknown, but could potentially lead to reduced
efficacy of naltrexone/bupropion.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): orphenadrine (HOS-130332) ifosfamide (HOS-091529) lead (HOS-085592) clopidogrel (HOS-087927) cyclophosphamide (HOS-084539) ticlopidine (HOS-087946)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-07T14:58:00Z · SHA-256 8d91203fd1313606105ccfcfeb588970833594eb1edb4edb571e8c8ed61c515c · Passage 2e9e72b24e46b32553a8091ca74aa11bb242b3cc556f555e7645ff504abc352c · Zeichen 4505–5089 im Abschnitt
Wechselwirkungen · Amglidia
AMGLIDIA 0.6 mg/mL oral suspension AMGLIDIA 6 mg/mL oral suspension · Abschnitt 4.5 · PDF-Seite 8–10
HOS-226728 · Präparat HOS-217644
Anabolic steroids and male Potentiation of the Hypoglycaemia
sex hormones blood-glucose lowering
effect
Barbiturates Weakening of the Increased blood-glucose
blood-glucose lowering levels
effect
Beta-receptor blockers Potentiation of the Hypoglycaemia
blood-glucose lowering
effect
Signs of adrenergic Incorrect control of plasma
counter-regulation to glucose
hypoglycaemia may be
reduced or absent
Biguanides Potentiation of the Hypoglycaemia
blood-glucose lowering
effect
Bosentan Increase liver enzymes Incorrect control of plasma
glucose
Calcium channel blockers Weakening of the blood- Increased blood-glucose
glucose-lowering effect levels
Chloramphenicol Potentiation of the Hypoglycaemia
blood-glucose lowering
effect
Cimetidine Weakening of the blood- Increased blood-glucose
glucose lowering effect levels
Clarithromycin Potentiation of the blood- Hypoglycaemia
glucose lowering effect
Clonidine Potentiation of the blood- Hypoglycaemia
glucose lowering effect
Potentiation or weakening of Incorrect control of plasma
the blood-glucose lowering glucose
effect
Signs of adrenergic counter- Incorrect control of plasma
regulation to hypoglycaemia glucose
may be reduced or absent
Weakening of the blood- Increased blood-glucose
glucose lowering effect levels
Colesevelam Reduction of glibenclamide Incorrect control of plasma
absorption from the glucose
gastrointestinal tract
Corticosteroids Weakening of the blood- Increased blood-glucose
glucose lowering effect levels
Coumarin derivatives Potentiation of the blood- Hypoglycaemia
glucose lowering effect
Potentiate or weaken the Incorrect dose of coumarin
effect of coumarin derivatives administered
derivatives
Cyclophosphamides Potentiation of the blood- Hypoglycaemia
glucose lowering effect
Diazoxide Weakening of the blood- Increased blood-glucose
glucose lowering effect levels
Disopyramide Potentiation of the blood- Hypoglycaemia
glucose lowering effect
Diuretics Weakening of the blood- Increased blood-glucose
glucose lowering effect levels
Fenfluramine Potentiation of the blood- Hypoglycaemia
glucose lowering effect
Fenyramidol Potentiation of the blood- Hypoglycaemia
glucose lowering effect
Fibrates Potentiation of the blood- Hypoglycaemia
glucose lowering effect
Fluoxetine Potentiation of the blood- Hypoglycaemia
glucose lowering effect
Glucagon Weakening of the blood- Increased blood-glucose
glucose lowering effect levels
Guanethidine Potentiation of the blood- Hypoglycaemia
glucose lowering effect
Signs of adrenergic counter- Incorrect control of plasma
regulation to hypoglycaemia glucose
may be reduced or absent
H2-receptor antagonists Potentiation or weakening of Incorrect control of plasma
the blood-glucose lowering glucose
effect
Heparin Potentiation of the blood- Hypoglycaemia
glucose lowering effect
Ifosfamide Potentiation of the blood- Hypoglycaemia
glucose lowering effect
Insulin Potentiation of the blood- Hypoglycaemia
glucose lowering effect
Isoniazid Weakening of the blood- Increased blood-glucose
glucoselowering effect levels
Large doses of laxatives Weakening of the blood- Increased blood-glucose
glucose lowering effect levels
Long-acting Potentiation of the blood- Hypoglycaemia
sulphonamides glucose lowering effect
MAO inhibitors Potentiation of the blood- Hypoglycaemia
glucose lowering effect
Miconazole Potentiation of the blood- Hypoglycaemia
glucose lowering effect
Nicotinic acid (in high Weakening of the blood- Increased blood-glucose
doses) glucose lowering effect levels
Oestrogens Weakening of the blood- Increased blood-glucose
glucose lowering effect levels
Other oral antidiabetics Potentiation of the blood- Hypoglycaemia
glucose lowering effect
Oxypentifylline Potentiation of the blood- Hypoglycaemia
glucose lowering effect
Oxyphenbutazone Potentiation of the blood- Hypoglycaemia
glucose lowering effect
Phenothiazine derivatives Weakening of the blood- Increased blood-glucose
glucose lowering effect levels
Phenytoin Weakening of the blood- Increased blood-glucose
glucose lowering effect levels
Phosphamides Potentiation of the blood- Hypoglycaemia
glucose lowering effect
Probenecid Potentiation of the blood- Hypoglycaemia
glucose lowering effect
Progestogens Weakening of the blood- Increased blood-glucose
glucose lowering effect levels
Quinolone antibiotics Potentiation of the blood- Hypoglycaemia
glucose lowering effect
Reserpine Potentiation of the blood- Hypoglycaemia
glucose lowering effect
Potentiation or weakening of Incorrect control of plasma
the blood-glucose lowering glucose
effect
Signs of adrenergic counter- Incorrect control of plasma
regulation to hypoglycaemia glucose
may be reduced or absent
Rifampicin Weakening of the blood- Increased blood-glucose
glucose lowering effect levels
Thyroid hormones Weakening of the blood- Increased blood-glucose
glucose lowering effect levels
Salicylates Potentiation of the blood- Hypoglycaemia
glucose lowering effect
Sulfamethoxazole with Potentiation of the blood- Hypoglycaemia
trimethoprim (Co- glucose lowering effect
trimoxazole)
Tetracycline compounds Potentiation of the blood- Hypoglycaemia
glucose lowering effect
Tritoqualine Potentiation of the blood- Hypoglycaemia
glucose lowering effect
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sulfamethoxazole (HOS-084533) trimethoprim (HOS-085184) fenfluramine (HOS-115627) tetracycline (HOS-115153) cimetidine (HOS-085835) clonidine (HOS-088594) diazoxide (HOS-088588) glucose (HOS-088412) coumarin (HOS-088372) heparin (HOS-086930) ifosfamide (HOS-091529) calcium (HOS-085615) disopyramide (HOS-085595) clarithromycin (HOS-084517) probenecid (HOS-085208) tritoqualine (HOS-115631) fluoxetine (HOS-085946) chloramphenicol (HOS-115623) guanethidine (HOS-088596) bosentan (HOS-086291) colesevelam (HOS-112356) isoniazid (HOS-088590) reserpine (HOS-088597) phenytoin (HOS-084531) glucagon (HOS-088589) miconazole (HOS-115630) oxyphenbutazone (HOS-226734)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2023-12-06T13:39:00Z · SHA-256 9b31c8fd2e2c11b31d3834841c43620453c6c194a0c4f4a1689401e4cae4ff04 · Passage 65768f222638b6ec5b55799dedba422cfd4ab929c394f7deccb2b45b8e583e53 · Zeichen 3453–12347 im Abschnitt
Wechselwirkungen · Pemazyre
Pemazyre 4.5 mg tablets Pemazyre 9 mg tablets Pemazyre 13.5 mg tablets · Abschnitt 4.5 · PDF-Seite 7
HOS-145609 · Präparat HOS-099381
Effect of pemigatinib on CYP2B6 substrates
In vitro studies indicate that pemigatinib induces CYP2B6. Co-administration of pemigatinib with
CYP2B6 substrates (e.g. cyclophosphamide, ifosfamide, methadone, efavirenz) may decrease their
exposure. Close clinical surveillance is recommended when pemigatinib is administered with these
medicinal products or any CYP2B6 substrate having a narrow therapeutic index.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): methadone (HOS-086198) ifosfamide (HOS-091529) cyclophosphamide (HOS-084539) efavirenz (HOS-087947)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-17T16:40:00Z · SHA-256 8e535a113ae402c5cf3666356fff94af919f2d5254b892ef44d65c6c6506d36b · Passage 8ad37e56ee4bec0e2d0f6ae20131782a01348306de26cb1a6a983a1503796dc4 · Zeichen 1855–2264 im Abschnitt
Wechselwirkungen · Thiotepa Riemser
Thiotepa Riemser 15 mg powder for concentrate for solution for infusion Thiotepa Riemser 100 mg powder for concentrate for solution for infusion · Abschnitt 4.5 · PDF-Seite 7
HOS-294844 · Präparat HOS-288098
Thiotepa is a weak inhibitor for CYP2B6, and may thereby potentially increase plasma concentrations
of substances metabolised via CYP2B6, such as ifosfamide, tamoxifen, bupropion, efavirenz and
cyclophosphamide. CYP2B6 catalyses the metabolic conversion of cyclophosphamide to its active
form 4-hydroxycyclophosphamide (4-OHCP) and co-administration of thiotepa may therefore lead to
decreased concentrations of the active 4-OHCP. Therefore, a clinical monitoring should be exercised
during the concomitant use of thiotepa and these medicinal products.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): bupropion (HOS-086329) tamoxifen (HOS-088380) ifosfamide (HOS-091529) lead (HOS-085592) cyclophosphamide (HOS-084539) efavirenz (HOS-087947) 4-hydroxycyclophosphamide (HOS-210375)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-07T13:43:00Z · SHA-256 80e2cd7daef8e1a97ffe5b9cf2bb130175af781c7421d5c5278d3b796091bf37 · Passage b77a97370501e485dfa7bd2e5a4e75a3576b5f42a59c92eb02cc46f9daba244f · Zeichen 992–1544 im Abschnitt
Wechselwirkungen · Voranigo
Voranigo 10 mg film-coated tablets Voranigo 40 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7
HOS-152390 · Präparat HOS-100749
Co-administration of vorasidenib with CYP2B6, CYP2C8, CYP2C9, CYP2C19, or CYP3A4 substrates
with narrow therapeutic index (including, but not limited to, amitriptyline, alfentanil, carbamazepine,
ciclosporin, dosulepin, everolimus, fentanyl, fosphenytoin, ifosfamide, imipramine, phenobarbital,
phenytoin, pimozide, quinidine, sirolimus, tacrolimus, tamoxifen, trimipramine, valproic acid, and
warfarin) may decrease the plasma concentrations of these medicinal products. Concomitant use of
substrates of these enzymes with narrow therapeutic index should be avoided in patients taking
vorasidenib.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): fosphenytoin (HOS-110222) alfentanil (HOS-109375) amitriptyline (HOS-085911) phenobarbital (HOS-085617) valproic acid (HOS-088515) trimipramine (HOS-152398) carbamazepine (HOS-085618) imipramine (HOS-085907) tamoxifen (HOS-088380) quinidine (HOS-085593) ifosfamide (HOS-091529) tacrolimus (HOS-085202) pimozide (HOS-085600) everolimus (HOS-086310) sirolimus (HOS-085172) fentanyl (HOS-086196) phenytoin (HOS-084531) warfarin (HOS-085950)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-27T16:33:00Z · SHA-256 2232f34043666605447d216a0f9efae95496605e48741a446bf6879643808d62 · Passage 3d550b9ad3b19c779ebfbf7d68a0ec9fc3073bab44b0453f3efc8e4f9e0983a9 · Zeichen 1607–2205 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.